Page last updated: 2024-09-02

ecteinascidin 743 and Blood Diseases

ecteinascidin 743 has been researched along with Blood Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Le Cesne, A; Reichardt, P	1
Anthoney, A; Beijnen, JH; Bowman, A; Gomez, J; Guzmán, C; Hanauske, A; Hoekman, K; Jimeno, J; Smyth, J; Twelves, C; Uiters, J; van Kesteren, C; Vermorken, JB; Wanders, J	1
Brahmer, J; Donehower, RC; Elsayed, Y; Ettinger, D; Hidalgo, M; Jimeno, A; Khan, Y; Laheru, D; Lansey, D; Messersmith, WA; Zannikos, P	1

Reviews

1 review(s) available for ecteinascidin 743 and Blood Diseases

Article	Year
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Disease Progression; Drug Administration Schedule; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic	2015

Article

Year

Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.

Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl

Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Disease Progression; Drug Administration Schedule; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic

2015

Trials

2 trial(s) available for ecteinascidin 743 and Blood Diseases

Article	Year
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dioxoles; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin	2003
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin	2008

Article

Year

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:13

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dioxoles; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin

2003

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin

2008